Hodkinson K E, Mahlangu J N
Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; National Health Laboratory Service, Johannesburg, South Africa.
S Afr Med J. 2017 Sep 22;107(10):859-863. doi: 10.7196/SAMJ.2017.v107i10.12443.
Venous thromboembolic disease (VTE) is a leading cause of morbidity and mortality worldwide. HIV and tuberculosis (TB) infections have an aetiological association with VTE. Implementation of national HIV and TB programmes in South Africa (SA) has changed the burden of these two conditions, with resultant effects on VTE prevalence. Furthermore, with the increased use of direct oral anticoagulants (DOACs), baseline thrombosis data are needed to evaluate the effect of these new agents.
To determine real-life baseline VTE characteristics in a pre-DOAC era, and to document the association of HIV and TB infections with VTE.
This was a single-centre prospective cohort study performed in a quaternary care centre at Charlotte Maxeke Johannesburg Academic Hospital, SA. Key inclusion criteria included signed informed consent by adults (≥18 years) with a new episode of thrombosis. Procedures included physical examination, thrombosis risk factor assessment, duplex Doppler examination, thrombophilia screening, inpatient treatment and outpatient follow-up.
Ninety-nine participants with confirmed thrombosis met the inclusion criteria. Participants were predominantly black (79.8%) and female (64.6%), with a median age of 46 (interquartile range (IQR) 38 - 57) years. The prevalences of HIV and TB were 53.0% and 21.2%, respectively. The most common risk factors for thrombosis were TB (17.2%) and malignancies (14.1%). Thrombophilia screening had a low diagnostic yield. The median time to target international normalised ratio during hospitalisation was 5.5 (IQR 4.0 - 7.0) days and the median duration of hospitalisation was 9 (IQR 7 - 11) days. The overall mortality rate in the cohort at 3 months post hospitalisation was 12.1%.
This prospective study provides real-life data on thrombosis diagnosis and management at a quaternary public healthcare facility, providing a valuable baseline against which the effect of new DOAC anticoagulants can be assessed. Further research is required to clarify the aetiological association between thrombosis and HIV and TB.
静脉血栓栓塞性疾病(VTE)是全球发病和死亡的主要原因。HIV和结核病(TB)感染与VTE存在病因学关联。南非(SA)国家HIV和TB项目的实施改变了这两种疾病的负担,进而影响了VTE的患病率。此外,随着直接口服抗凝剂(DOACs)使用的增加,需要基线血栓形成数据来评估这些新药的效果。
确定DOAC时代之前的真实生活基线VTE特征,并记录HIV和TB感染与VTE的关联。
这是一项在南非约翰内斯堡夏洛特·马克西克学术医院的四级护理中心进行的单中心前瞻性队列研究。主要纳入标准包括18岁及以上有新发血栓形成事件的成年人签署知情同意书。程序包括体格检查、血栓形成危险因素评估、双功多普勒检查、易栓症筛查、住院治疗和门诊随访。
99名确诊血栓形成的参与者符合纳入标准。参与者主要为黑人(79.8%)和女性(64.6%),中位年龄为46岁(四分位间距(IQR)38 - 57岁)。HIV和TB的患病率分别为53.0%和21.2%。血栓形成最常见的危险因素是TB(17.2%)和恶性肿瘤(14.1%)。易栓症筛查的诊断率较低。住院期间达到目标国际标准化比值的中位时间为5.5天(IQR 4.0 - 7.0),中位住院时间为9天(IQR 7 - 11)。队列在住院后3个月的总死亡率为12.1%。
这项前瞻性研究提供了四级公共医疗机构血栓形成诊断和管理的真实生活数据,为评估新型DOAC抗凝剂的效果提供了有价值的基线。需要进一步研究以阐明血栓形成与HIV和TB之间的病因学关联。